{
  "ADD_TRANSACTION": "New Record",
  "SEQUENCE_NUM": "Sequence Number",
  "NEW":"NEW",
  "EXISTING":"EXISTING",
  "DATE_SUBMITTED": "Date Submitted (YYYY-MM-DD)",
  "SEQUENCE_DESCRIPT": "Regulatory Transaction Description",
  "IS_ACTCHANGES": "Same as Regulatory Activity Contact for this Submission?",
  "COMPANY_ID": "Company Identifier",
  "DOSSIER_ID": "Dossier Identifier",
  "DOSSIER_NAME": "Dossier Name",
  "IS_ECTD": "Is this an eCTD transaction?",
  "IS_SOLICITED": "Is this solicited information?",
  "SOLICITED_RQ": "Requester of Solicited Information",
  "SOLICITED_RQ_OTHER": "Other Requester Details",
  "REP_CONTACT_INFO": "Main Contact Information",
  "PROJ_MANAGER_NAME": "Name of Regulatory Project Manager, if known",
  "DATED": "Dated (YYYY-MM-DD)",
  "START_DATE": "Start Date (YYYY-MM-DD)",
  "END_DATE": "End Date (YYYY-MM-DD)",
  "REG_ACTIVITY": "Regulatory Activity",
  "REG_ACTIVITY_TYPE": "Regulatory Activity Type",
  "SEQUENCE_TYPE": "Regulatory Transaction Description",
  "VERSION_NO": "Version Number",
  "BRIEF_DESC": "Brief Description",
  "BRIEF_DESC_CHANGE": "Brief Description of change",
  "ADMINISTRATIVE": "Administrative",
  "BENEFIT_RISK_ASSESS": "Benefit Risk Assessment",
  "CANCEL_LETTER": "Cancellation Letter",
  "CHANGE_TO_DIN": "Change to DIN",
  "COMMENTS_NOC": "Comments on Notice of Decision",
  "COMMENTS_SUMMARY_BASIS": "Comments on Summary Basis of Decision (SBD)",
  "COMMENTS_REGULARTORY_DECISION": "Comments on Regulatory Decision Summary",
  "DIN_DISCONTINUED": "Notification of Discontinued Sale (DIN Cancellation)",
  "DRUG_NOTIF_FORM": "Drug Notification Form",
  "FOR_PERIOD": "For Period of",
  "INITIAL": "INITIAL",
  "MEETING_MINUTES": "Minutes of Meeting",
  "NOTIFICATION_CHANGE": "Notification of Change in Benefit-Risk Profile",
  "NOTIFICATION_INTERRUPT_SALE":"Notification Interruption of Sale",
  "PANDEMIC_APPL": "Pandemic Application",
  "POST_CLEARANCE_DATA": "Post Clearance Data",
  "POST_MARKET_SURV": "Post Marketing Surveillance",
  "POST_NOC_CHANGE": "Post NOC Change",
  "POST_AUTH_DIV1_CHANGE": "Post-Authorization Division 1 Change",
  "PRESUB_MEETING_PKG": "Submission Meeting Package",
  "PRESUB_MEETING_RQ": "Submission Meeting Request",
  "PRIORITY_REVIEW_RQ": "Priority Review Request",
  "PRISTINE_PM": "Pristine PM",
  "SECOND_LANG_PM": "Second Language PM",
  "PRISTINE_PM_2LANG": "Second Language PM and Final Package Insert",
  "ADVISEMENT_LETTER_RESPONSE": "Response to Advisement Letter",
  "CLIN_CLARIF_RESPONSE": "Response to Clinical Clarification Request",
  "EMAIL_RQ_RESPONSE": "Response to E-mail Request",
  "HSC_RQ_RESPONSE": "Response to Human Safety Clarification Request",
  "QHSC_RQ_RESPONSE": "Response to Quality & Human Safety Clarification Request",
  "CHSC_RQ_RESPONSE": "Response to Clinical & Human Safety Clarification Request",
  "QCHSC_RQ_RESPONSE": "Response to Quality, Clinical and Human Safety Clarification Request",
  "LABEL_CLARIF_RESPONSE": "Response to Labeling Clarification Request",
  "MHPD_RQ_RESPONSE": "Response to MHPD Request",
  "NOC_RESPONSE": "Response to NOC/c-QN",
  "NOD_RESPONSE": "Response to NOD",
  "NON_RESPONSE": "Response to NON",
  "NOL_RESPONSE": "Response to NOL",
  "PROCESSING_CLARIF_RESPONSE": "Response to Processing Clarification Request",
  "QUAL_CLIN_CLARIF_RESPONSE": "Response to Quality & Clinical Clarification Request",
  "QUAL_CLARIF_RESPONSE": "Response to Quality Clarification Request",
  "SCREENING_ACCEPT_RESPONSE": "Response to Screening Acceptance Letter",
  "SCREENING_CLARIF_RESPONSE": "Response to Screening Clarification Request",
  "SDN_RESPONSE": "Response to SDN",
  "PHONE_RQ_RESPONSE": "Response to Telephone Request",
  "RISK_COMMUN_DOC": "Risk Communication Document",
  "RMP_VERSION_DATE": "RMP",
  "SIGNAL_WORK_UP": "Signal Work Up",
  "UNSOLICITED_DATA": "Unsolicited Information",
  "YEAR_LIST_OF_CHANGE": "Year(s) of change, list of change number(s) ",
  "NONCLIN_CLARIF_RESPONSE": "Response to Non-clinical Clarification Request ",
  "BE_CLARIF_RESPONSE": "Response to BE Clarification Request",
  "RECON_DECIS_LTR_INTENT": "Reconsideration of Decision - Letter of Intent",
  "RECON_DECIS_RQ_RECON":  "Reconsideration of Decision - Request for Reconsideration",
  "RECON_DECIS_OTHER_INFO": "Reconsideration of Decision - Other Information",
  "LABEL_PREAPPROVAL_2LANG":"Second Language Label - Pre-Approval",
  "LIFECYCLE_TITLE": "Transaction Details",
  "REG_CONTACT_THIS": "Contact for THIS Regulatory Activity",
  "REG_ACT_CONTACT": "Regulatory Activity Contact",
  "TRANSACTION_HDING": "Regulatory Information",
  "LOAD_TRANSACTION": "Load a Regulatory Transaction File",
  "COMPANY_INFO": "A. Company Information",
  "ADDRESS_INFO": "B. Address Information",
  "COMPANY_REP_THIS": "C. Company Representative",
  "GENERATE_FINAL": "Generate Final XML",
  "CONFIRM_CONTACT_VALID": "I confirm that the above regulatory activity contact information is valid.",
  "YEAR_CHANGE": "Year(s) of change, list of change number(s)",
  "YEARS": "Year",
//  "REG_ACTIVITY_INSTRUCT":"Regulatory Activity Contact Instructions",
//  "SAVE_INSTRUCT": "Transaction File Save Instructions",
  "CLARIF_RESPONSE":"Response to Clarification Request",
  "CORR_PATENT_MED":"Correspondence - Patented Medicines",
  "ALLEGATION_NOTICE":"Notice of Allegation",
  "FORM_IV":"Form IV",
  "FORM_V":"Form V",
  "CONSENT_LTR":"Consent Letter",
  "DATA_PROTECT_CORRESP":"Correspondence - Data Protection",
  "CHOOSE_REQUEST":"Choose a requester",
//  "TRANSACT_INSTRUCT":"Regulatory Transaction Instructions",
  "LIST_DESCRIPT":"List Description",
  "SEQUENCE_CLEANUP":"eCTD Dossier Clean-up",
  "ADV_COMP_REQ": "Advertising Complaint Request for Information",
  "CSOtRMP": "Canadian Specific Opioid RMP",
  "DISSEM_LIST": "Dissemination List",
  "FOREIGN_SAFETY_NOTIFICATION": "Foreign Safety Action Notification",
  "ISSUE_SAFETY_REQUEST": "Issue Related Safety Request",
  "PATIENT_SAFETY_INFO": "Patient Safety Information (Medication error)",
  "PUB_RELEASE_INFO": "Public Release of Clinical Information",
  "RESSESS_ORDER": "Reassessment Order",
  "WRITTEN_CONSULT_REQ": "Request for Written Consultation",
  "TEST_STUDIES_ORDER": "Test and Studies Order",
  "TERM_COND_COMM": "Terms and Conditions Commitment",
  "YEAR": "Year",
  "CTN_ADMINISTRATIVE":"CTN-Administrative Change to",
  "CTN_APPENDIX":"CTN-Appendix",
  "CTN_CONTACT":"CTN-Contact Change",
  "CTN_CROSS":"CTN-Cross Reference Letter",
  "CTN_DATA":"CTN-Data Safety Monitoring Committee",
  "CTN_DEAR":"CTN-Dear Investigator/Doctor Letter",
  "CTN_DILUENT":"CTN-Diluent Change",
  "CTN_DRUG_PROD":"CTN-Drug Product Change",
  "CTN_DRUG_SUBS":"CTN-Drug Substance change",
  "CTN_ENROLLMENT":"CTN-Enrollment Suspension",
  "CTN_ETHICS":"CTN-Ethics Board Communications",
  "CTN_EXCLUSION_INCLUSION":"CTN-Exclusion/Inclusion Criteria Revision",
  "CTN_INFORMED":"CTN-Informed Consent Form Update",
  "CTN_INVESTIGATOR":"CTN-Investigator’s Brochure Update",
  "CTN_NEW_MANUFACTURING":"CTN-New Manufacturing Site for",
  "CTN_NEW_PKG":"CTN-New Packaging/Labelling Site",
  "CTN_NEW_QC":"CTN-New QC Testing Site",
  "CTN_NOL":"CTN-NOL Response",
  "CTN_PACKAGING_LABELLING":"CTN-Packaging/Labelling Name Change",
  "CTN_PM":"CTN-PM Update",
  "CTN_PROTOCOL_INFO_UPDATE":"CTN-Protocol and Informed Consent Form Update",
  "CTN_PROTOCOL_UPDATE":"CTN-Protocol Update/Change",
  "CTN_QOS":"CTN-QOS Update",
  "CTN_REFUSALS":"CTN-Refusals by Foreign Regulatory Authorities/REBs",
  "CTN_REGULATORY":"CTN-Regulatory Hold",
  "CTN_RESPONSE":"CTN-Response to Information Request",
  "CTN_SAFETY":"CTN-Safety Update",
  "CTN_SHELF_PD":"CTN-Shelf Life Extension for DP",
  "CTN_SHELF_DS":"CTN-Shelf Life Extension for DS",
  "CTN_SITE":"CTN-Site Closure",
  "CTN_SOURCE":"CTN-Source Change of",
  "CTN_STRAIN":"CTN-Strain Change",
  "CTN_STUDY_COMPLETION":"CTN-Study Completion",
  "CTN_STUDY_DISC":"CTN-Study Discontinuation due to",
  "CTN_STUDY_EXT":"CTN-Study Recruitment Timeline Extension",
  "CTN_STUDY_SUS":"CTN-Study Suspension",
  "CTN_TRANS_OWN":"CTN-Transfer of Ownership",
  "CTN_FORM_BROC_UPDATES":"CTN-Informed Consent Form and Investigator’s Brochure Updates",
  "CTN_IMPD_UPDATE":"CTN-IMPD Update",
  "CTN_NEW_SUMM_ADF":"CTN-New Summary of Additional Drugs Form",
  "CLINICAL":"CLINICAL",
  "CLINICAL_QUALITY":"CLINICAL & QUALITY",
  "QUALITY":"QUALITY",
  "INITIAL_TEAT_SOLU_MONO":"INITIAL - Teat Solutions Monograph",
  "REQ_ACCEPTED":"Request Accepted",
  "SND_LANG_PM": "Second Language PM",
  "REQUESTER_NAME":"Name of requester",
  "REQUESTER_NAME2":"Name of requester",
  "DEFER_FEES":" A deferral of payment is requested with this transaction.",
  "DEFER_STATEMENT":"The statement supporting the deferral request is included.",
  "FEE_REMISSION":"Fee Remission is requested with this transaction",
  "STATEMENT_REVENUE":"A statement signed by the individual responsible for the applicant's financial affairs is included to certify that the fee payable is greater than 10% of the anticipated gross revenue",
  "SUB_CLASS":"Submission Class",
  "FEE_AMOUNT":"Fees",
  "FEE_DESCRIPTION":"Submission Description",
  "REMISSION_ELIGIBLE":"You are eligible to apply for fee remission. The submission fee is greater than 10% of anticipated gross revenues.",
  "REMISSION_INELIGIBLE":"You are not eligible to apply for fee remission. The submission fee is less than 10% of anticipated gross revenues.",
  "IS_FEE_TRANSACTION":"Are new or revised fees associated with this transaction?",
  "REGULATORY_FEES":"Fees",
  "GROSS_REVENUE":"Anticipated gross revenue for this drug product during the fee verification period",
  "TEN_PERCENT_REVENUE": "10% of anticipated gross revenue",
  "REQUIRED_DOC":"Required Documentation",
  "SUPPORTING_DOC":"Please include the required signed statement AND at least one of the support documentation to establish that the applicable fee payable is greater than 10% of the anticipated gross revenue from sales of the drug product in Canada during the fee verification period.",
  "EST_MARKET_SHARE":"Estimated market share (that is [i.e.], product's market potential compared to the total market for similar products in Canada)",
  "SIMILAR_PRODUCT":"Comparison to similar products on the Canadian market or other similar markets (e.g., United States, European Union)",
  "SALES_HISTORY":"Sales history prior to product upgrades or sales history of similar products",
  "MARKETING_PLAN":"Marketing plan/product plan for the drug product",
  "AVG_SALES":"Average sale price and demand",
  "FEES_LESS10K":"Fees of $10,000 or less must be paid at the time of filing of the submission, supplement or application. Please complete the",
  "ADVANCE_PAYMENT":"Advance Payment Details for Drug Submissions and Master Files.",
  "SPONSOR_INVOICE":"Review fees must not be included with the submission, supplement or application. Sponsors will be invoiced for fees of more than $10,000.",
  "PAYMENT_METHODS":"Please select all the payment methods you intend to use",
  "ONE_PAYMENT_METHOD":"Please select all the payment methods you intend to use",
  "ONE_FEE_DOC":"At least one of the support documentation to establish that the applicable fee payable is greater than 10% of the anticipated gross revenue from sales of the drug product in Canada during the fee verification period",
//  "DEFER_INSTRUCT":"Deferral of Payment Instructions",
//  "REMISSION_INSTRUCT":"Fee Remission Instructions",
//  "CLASS_INSTRUCT":"Submission Class Instructions",
//  "PRODUCT_INSTRUCT":"Product Name Instructions",
//  "LIFECYCLE_INSTRUCT":"Lifecycle Management Table Instructions",
//  "SEQUENCE_INSTRUCT":"Sequence Number Instructions",
//  "CONTROL_INSTRUCT":"Control Number Instructions",
//  "COMPANY_INSTRUCT":"Company Name Instructions",
//  "COMPANY_ID_INSTRUCT":"Company ID Instructions",
//  "DOSSIER_ID_INSTRUCT":"Dossier ID Instructions",
//  "ADMIN_COMP_INSTRUCT": "Administrative Submission or Component Instructions",
  "PLEASE_REMIT":"Please pay the remission processing fee of $590 using the Advance Payment Details for Drug Submissions and Master Files.",
  "APPLY_DEFER":"You are applying for a deferral. Please send no payment with this form.",
  "BANK_DRAFT":"International Bank Draft",
  "MONEY_ORDER":"Money Order",
  "CHEQUE":"Cheque",
  "PAYMENT":"Payment",
  "CREDIT":"MasterCard/Visa/American Express (AMEX)",
  "BANK_WIRE":"Wire (include bank confirmation)",
  "EXISTING_CREDIT":"Existing credit",
  "PREFEERED_OPTION":"Bill Payment Service Option (preferred method)",
  "REG_TRANSACT":"Regulatory Transaction",
  "LIFE_REC":"Transaction Details Record",
  "ONELIFEREC": "One transaction details record is required.",
  "SAVELIFEREC": "One transaction details record is required to save.",
  "LIFECYCLECTRL.LIFECYCLEDETAILSFORM":"with a Transaction Details Record",
  "IS_NEW_ACTIVITY":"Is this transaction for a new or existing regulatory activity?",
  "IS_SIGNED_3RD_PARTY": "Will the submission be signed / filed by a third party on behalf of the manufacturer / sponsor?",
  "AUT_LETTER_NOTE": "A letter of authorization signed by the manufacturer/sponsor company must be provided in section 1.2.1 of the regulatory transaction.",
  "IS_PRIORITY":"Was this regulatory activity approved for priority review?",
  "IS_NOC":"Was this regulatory activity approved for NOC/C review?",
  "IS_ADMIN_SUBMISSION": "Is this regulatory activity an Administrative Submission or does this regulatory activity contain an administrative component?",
  "ADMIN_DESCRIPT":"Administrative Submission or administrative component description",
  "ADMIN_SUB_TYPE":"Reason for Administrative Submission or administrative component",
  "ACTIVITY_LEAD": "Regulatory Activity Lead",
  "OTHER_DOC_DETAILS": "Other Documentation Details",
  "B14-20160301-09":	"Pharmaceutical",
  "B14-20160301-02":	"Biological",
  "B14-20160301-10":	"Post-Market Vigilance",
  "B14-20160301-06":	"Consumer Health Product",
  "B14-20160301-11":	"Veterinary",
  "B14-20160301-04":	"Clinical Trial - Biologics",
  "B14-20160301-05":	"Clinical Trial - Pharmaceutical",
  "RESET": "RESET",
  "RESET_INFO" : "To enable the 'generate final XML' button, select the 'RESET' button to clear transaction specific fields.",
  "FEE_REMIT_NO_PAYMENT" :"Please remit no payment with this transaction. Payment of the fees will be required upon issuance of an invoice",
  "MITIGATION_TYPE" : "The following mitigation measures are available (select one). Sponsors must certify that they meet the criteria as outlined in the Food and Drug Regulations.",
  "CERTIFY_ORGANIZATION" : "We certify that we meet the definition of small business and have registered our company with Health Canada prior to submitting this submission/application. We understand that failure to register as a small business prior to submitting this submission/application will result in the full fee being charged.",
  "CERTIFY_ORGANIZATION_A" : "a total number of employees less than 100 people, or",
  "CERTIFY_ORGANIZATION_B" : "a total annual gross revenue between $30,000 and $5 million.",
  "SMALL_BUSINESS_FEE_APPLICATION":"We have not previously filed a submission/application in respect of a drug with Health Canada. We are filing our first submission/application.",
  "FIRST_SUBMISSION" : "This is my first submission/application",
  "CERTIFY_GOVERMENT_ORGANIZATION" : "We certify that our organization is a branch or agency of the Government of Canada or of a province or territory",
  "CERTIFY_URGENT_HEALTH_NEED":"We certify that the drug in our submission/application is on the List of Drugs for an Urgent Public Health Need as per the Access to Drugs in Exceptional Circumstances Regulations AND",
  "DRUG_THE_SAME_INGREDIENT":"the drug has the same medicinal ingredient, strength and route of administration, and is in a comparable dosage form, as a drug that may be imported under subsection C.10.001(2) of those Regulations;",
  "NO_DRUG_IDENTIFICATION_NUMBER":"no drug identification number has been assigned under section C.01.014.2 of those Regulations for the drug or for another drug that has the same medicinal ingredient, strength and route of administration and is in a comparable dosage form; and",
  "NO_NOTICE_COMPLIANCE":"no notice of compliance has been issued under section C.08.004 of those Regulations in respect of the drug or another drug that has the same medicinal ingredient, strength and route of administration and is in a comparable dosage form.",
  "CERTIFY_FUNDED_HEALTH_INSTITUTION":"We certify that our institution is funded by the Government of Canada or the government of a province or territory and that it is",
  "CERTIFY_FUNDED_HEALTH_INSTITUTION_A":"licensed, approved or designated by a province in accordance with the laws of the province to provide care or treatment to persons or animals suffering from any form of disease or illness; or",
  "CERTIFY_FUNDED_HEALTH_INSTITUTION_B":"owned or operated by the Government of Canada or the government of a province and that provides health services.",
  "TYPE_MIN": "End Date should not be earlier than Start Date.",
  "FEE_PAY_NOTICE": "Do not send fee payment with your submission, supplement or application. Health Canada will verify the fee and issue an invoice accordingly.",
  "MITIGATION_MEASURES": "Mitigation Measures",
  "PROD_PROTOCOL": "Protocol Number",
  "CTA_FROM": "From [time]",
  "CTA_TO": "To [time]",
  "COVIR-19": "COVID-19 Interim Order Application",
  "COVIR-19AMD": "COVID-19 Interim Order Ap - Amendment",
  "HT_LOAD_FILE_1": "A file should not be loaded if it is the first REP transaction for this dossier.",
  "HT_LOAD_FILE_2": "When continuing with a working copy, the format of the file to load should be .hcsc.",
  "HT_LOAD_FILE_3": "When viewing/updating a final XML file, the format of the file to load should be .xml.",
  "HT_DOSSIER_TYPE_1": "Biologic dossier applies to all biologic products and radiopharmaceuticals",
  "HT_DOSSIER_TYPE_2": "Pharmaceutical dossier applies to all pharmaceutical products for human use, non-prescription and ethical products, disinfectants",
  "HT_DOSSIER_TYPE_3": "Clinical Trial dossier applies to all pharmaceutical products for human use, biologic products and radiopharmaceuticals, non-prescription and ethical products, and disinfectants",
  "HT_DOSSIER_TYPE_4": "Veterinary dossier applies to all pharmaceuticals for veterinary use, non-prescription and ethical products",
  "HT_COMP_ID_1": "The Company Identifier must be obtained from the final company XML file, issued by Health Canada.",
  "HT_COMP_ID_2": "Company Identifier must be 5 digits, add leading zero when required.",
  "HT_DOSSIER_ID": "Dossier Identifier - The dossier identifier is a code created by Health Canada to uniquely identify the dossier.  For existing dossiers the dossier ID can be verified from the Drug Submission Tracking System – Industry Access (DSTS-IA).  If a dossier ID has not yet been assigned, sponsors must request for one using the appropriate form, available on the REP information webpage.",
  "HT_DOSSIER_ID_0": "The format of a Dossier Identifier is a letter followed by six digits. (e.g. HC6-024-x######). For example in this field you would need to enter one of the following depending on the dossier type:",
  "HT_DOSSIER_ID_1": "eCTD formatted dossier – e######",
  "HT_DOSSIER_ID_2": "Non-eCTD formatted Pharmaceutical/Biological dossier for Division 1 Human drugs – d######",
  "HT_DOSSIER_ID_3": "Non-eCTD formatted Pharmaceutical/Biological dossier for Division 8 Human drugs – p######",
  "HT_DOSSIER_ID_4": "Non-eCTD formatted Pharmaceutical/Biological dossier for Division 5 Human drugs – c######",
  "HT_DOSSIER_ID_5": "Non-eCTD formatted Pharmaceutical/Biological dossier for Veterinery Drugs drugs – v######",
  "HT_PROD_NAME_1": "Only include the name of the products impacted by this regulatory activity. For multiple products, list and separate their product names with a semi-colon (;)." ,
  "HT_PROD_NAME_2": "The product name is the name assigned by the manufacturer/sponsor to distinguish the drug (product) and under which the drug is to be sold/advertised. It is also the name used to identify the product in all correspondence related to the submission and on the product label(s) and Product Monograph and/or Package Insert, if applicable. If the brand name has not yet been determined, the proper or common name of the drug or research code may be used.",
  "HT_PROD_NAME_3": "The product name input in this field will only be reviewed with the initial transaction of a dossier (i.e. sequence 0000 for eCTD format). For all subsequence transactions, any changes to the product name should be captured and will be reviewed using the product information template. Product name changes on this template will not be reviewed.",
  "HT_PROD_NAME_4": "For clinical trials: Please enter the name of the investigational product, and where there is more than one investigational product, all of them should be captured. An investigational product corresponds to a product involved in the conduct of a clinical trial. It could be a product not available in Canada, a product in development or a product already approved in Canada but used outside the approved indication.",
  "HT_PROTOCOL_NUM":"The protocol number must be assigned by the sponsor for each protocol when submitting a clinical trial application (CTA) to Health Canada. Sponsors are encouraged to include a protocol number for Pre-CTA meeting requests if available. In general, a protocol number is a variable length, alpha-numeric sequence used by sponsors to assign a reference number to their protocol. The protocol number for clinical trials should remain the same for the duration of the trial. When updating their documents, including protocols, sponsors should, in accordance with their internal record/document management practices, apply version control principles. When submitting a CTA-Amendment or Notification, sponsors should indicate the version or amendment number of the protocol. For more information on the correct numbering of the protocol version or amendment provided in CTA-A or CTA-N, please consult the",
  "HT_PROTOCOL_NUM_SUB":" Guidance for Completing the Drug Submission Application Form",
  "HT_PROTOCOL_NUM_SUB_URL":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/forms/guidance-completing-drug-submission-application-form.html",
  "HT_REFER_TO": "Refer to the",
  "HT_ADMIN_SUB": "Guidance Administrative Processing of Submissions and Applications: Human or Disinfectant Drugs",
  "HT_ADMIN_SUB_URL": "https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/guidance-administrative-processing-human-disinfectant-drugs.html",
  "HT_CTRL_NUM_1": "Enter the 6 digit control number associated with this regulatory activity (if known).",
  "HT_CTRL_NUM_2": "Enter “000000” for regulatory transactions that Do Not require a control number (e.g. Level III - Post-NOC Changes, UDRA – DIN cancellations, UDRA - Notification Interruption of sale, UDRA -  eCTD Dossier Clean-up).",
  "HT_CTRL_NUM_3": "Enter “000000” for the first transaction of a NEW regulatory activity, where a control number has not yet been assigned.",
  "HT_CTRL_NUM_4": "Enter the pre-assigned control number for the first transaction of a new regulatory activity that was communicated by Health Canada (e.g. via an Advisement Letter).",
  "HT_CTRL_NUM_5": "Drug Notification Form(s) (DNF) should be filed under the same control number it has been issued for the product(s) that are now being sold on the market.",
  "HT_ACT_LEAD_1": "Biological: Includes all regulatory activities and transactions under the Biologics and Genetic Therapies Directorate (BGTD) mandate (biologics/radiopharmaceuticals).",
  "HT_ACT_LEAD_2": "Clinical Trial – Biologics: Includes all regulatory activities and transactions for clinical trials for biologics under the Biologics and Genetic Therapies Directorate (BGTD) mandate.",
  "HT_ACT_LEAD_3": "Clinical Trials – Pharmaceuticals: Includes all regulatory activities and transactions for clinical trials for prescription pharmaceuticals under the Therapeutic Products Directorate (TPD) mandate and  for biologics under the Biologics and Genetic Therapies Directorate (BGTD) mandate",
  "HT_ACT_LEAD_4": "Consumer Health Products: Includes all regulatory activities and transactions for non-prescription pharmaceuticals and disinfectants under the Natural and Non-Prescription Health Products Directorate (NNHPD) mandate.",
  "HT_ACT_LEAD_5": "Pharmaceutical: Includes all regulatory activities and transactions for prescription pharmaceuticals and ethical products under the Therapeutic Products Directorate (TPD) mandate.",
  "HT_ACT_LEAD_6": "Post-Market Vigilance: Includes all regulatory activities and transactions under the Marketed Health Products Directorate (MHPD) mandate (prescription and non-prescription pharmaceuticals for human use, biologics, radiopharmaceuticals).",
  "HT_ACT_LEAD_7": "Veterinary: Includes all regulatory activities and transactions for prescription and non-O33prescription pharmaceuticals under the Veterinary Drugs Directorate (VDD) mandate.",
  "HT_YEAR_CHANGE_1": "For pharmaceuticals for veterinary and human use, biologics and radiopharmaceuticals, refer to the: ",
  "HT_YEAR_CHANGE_2": "Post-Notice of Compliance (NOC) Changes: ",
  "HT_YEAR_CHANGE_3": "Quality Guidance",
  "HT_YEAR_CHANGE_4": "Safety and Efficacy",
  "HT_YEAR_CHANGE_URL_1": "https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/post-notice-compliance-changes/quality-document.html",
  "HT_YEAR_CHANGE_URL_2": "https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/post-notice-compliance-changes/safety-efficacy-document.html",
  "HT_YEAR_CHANGE_5": "For pharmaceuticals for veterinary use, also refer to:",
  "HT_YEAR_CHANGE_6": "Guidance for Industry Preparation of Veterinary New Drug Submissions for innovative drugs",
  "HT_YEAR_CHANGE_7": "Guidance for Industry – Preparation of Veterinary Abbreviated New Drug Submissions – Generic Drugs for generic drugs ",
  "HT_YEAR_CHANGE_URL_3": "https://www.canada.ca/en/health-canada/services/drugs-health-products/veterinary-drugs/legislation-guidelines/guidance-documents/guidance-industry-preparation-veterinary-new-drug-submissions-health-canada-2007.html",
  "HT_YEAR_CHANGE_URL_4": "https://www.canada.ca/en/health-canada/services/drugs-health-products/veterinary-drugs/legislation-guidelines/guidance-documents/guidance-industry-preparation-veterinary-abbreviated-new-drug-submissions-generic-drugs-health-canada-2009-1.html",
  "HT_YEAR_CHANGE_8": "Include the year that the change took place, the name of the guidance document and the number or letter of the corresponding change in the appropriate guidance document, when applicable. ",
  "HT_YEAR_CHANGE_9": "2018; Post-NOC Changes: Quality; 15, 18, 23",
  "HT_YEAR_CHANGE_10": "June 2017 to May 2018 14, 16, 27",
  "HT_YEAR_CHANGE_11": "2016, 2017, 2018, 5, 8, 17",
  "HT_YEAR_CHANGE_12": "For pharmaceuticals for human use, biologics and radiopharmaceuticals, refer to the: ",
  "HT_YEAR_CHANGE_13": "For example: ",
  "HT_YEAR_CHANGE_14": "Include the year that the change took place, the name of the guidance document and the number or letter of the corresponding change in the appropriate guidance document, when applicable. Otherwise, briefly describe the change:",
  "HT_DESC_CHANGE_1": "Reference the applicable appendix or sections of the Post-Notice of Compliance (NOC) Changes Guidance Documents and identify the changes.",
  "HT_DESC_CHANGE_2": "i.e. Quality Document- 3.2.S Drug Substance #1, 2d, 9b, 17,",
  "HT_DESC_CHANGE_3": "i.e. Quality Document - 3.2.S Drug Substance (Kits/radiopharmaceuticals containing drug substance of chemical origin) - #3, 9, 10c",
  "HT_DESC_CHANGE_4": "i.e.  Safety and Efficacy Document -  Supplements - a, d.",
  "HT_REQ_SOL": "If the name of the requester is unknown, enter the generic email the request was sent from.",
  "HT_FROM": "Time should be entered in this format: number, followed by one of the words hours, days or months.",
  "HT_FEES_1": "For more information related to fees, refer to the",
  "HT_FEES_2": "Guidance Document - Fees for the Review of Drug Submissions and Applications",
  "HT_FEES_URL": "https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/fees/fees-review-drug-submissions-applications.html",
  "HT_CONTACT_1": "Information provided here pertains to the contact specific to the subject regulatory activity, i.e., the person/company to whom Health Canada should direct correspondence about the subject regulatory activity.",
  "HT_CONTACT_2": "the contact specific to the subject regulatory activity,",
  "HT_CONTACT_3": " i.e., the person/company to whom Health Canada should direct correspondence about the subject regulatory activity.",
  "HT_CONTACT_4": "Please note that it is up to the discretion of Health Canada to decide the method of correspondence.",
  "HT_CONTACT_5": "If you are adding a record to previously submitted final regulatory transaction xml, these fields will be prepopulated with the information of the previous transaction (sequence number).",
  "HT_CONTACT_6": "Sponsors should update this information if required; otherwise confirm that the information is still valid.",
  "HT_CONTACT_7": "Enter the name of the company to which the regulatory activity contact belongs. If the contact does not belong to a company, enter the name of the contact.",
  "HT_COMP_NAME_1": "If the company differs from the sponsor, a letter of authorization signed by the manufacturer/sponsor must be provided in section 1.2.1 of the regulatory transaction.",
  "HT_COMP_NAME_2": "If the company differs from the sponsor, a letter of authorization signed by the manufacturer/sponsor must be provided in: ",
  "HT_COMP_NAME_3": "Human Drugs - section 1.2.1 of the transaction using REP",
  "HT_COMP_NAME_4": "Veterinary Drugs - section 1.4 of the transaction using REP",
  "ROUTING_ID_1": "The routing identifier is a unique identifier within the Common Electronic Submissions Gateway (CESG) used to identify specific gateway account, whether it uses the Applicability Statement 2 (AS2) or WebTrader interfaces.",
  "ROUTING_ID_2": "For the WebTrader users, the routing identifier is automatically assigned to each account by the system. It can be retrieved from the receipt message. Navigate to the WebTrader Inbox, click on “Receipt”, “View” document. Document Content page opens up and the routing identifier can be found under attribute: “X-Cyclone-To:”",
  "ROUTING_ID_3": "For the AS2 users, the routing identifier has to be created by the company. It is recommended that the company's data universal numbering system number be used, but any alpha-numeric text string is acceptable.",
  "ROUTING_ID_5": "For any further questions on the routing identifier, please contact the Food and Drug Administration Help Desk at ",
  "ROUTING_ID_4": "The routing identifier could be the same for the manufacturer / sponsor contact and regulatory / annual contact. The Canadian importer would have a separate routing identifier.",
  "HT_XML_1": "A final regulatory transaction XML file must be included in section 1.2.1 for each of your REP transactions.",
  "HT_XML_2": "Refer to the REP guidance document for detailed information.",
  "HT_XML_3": "A final regulatory transaction XML file must be included in: ",
  "HT_XML_4": "Human Drugs - :section 1.2.1 of the transaction using REP",
  "HT_XML_5": "Veterinary Drugs - section 1.5 of the transaction using REP",
  "NOTICE_APR_2020":"Important Note: This template includes the revised Fees effective April 1, 2020 and should be used for regulatory transactions intended for filing on or AFTER April 1, 2020."
}